# US 2023/0054211 A1 · Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054211 A1
- Document ID: US20230054211A1
- Status: Published application
- Kind: A1
- Application number: 17/887,962
- Filed: 2022-08-15
- Published: 2023-02-23
- Earliest claimed: 2021-08-06
- Assignees: Transcend Therapeutics, Inc.
- Applicants: Transcend Therapeutics, Inc.
- Inventors: Blake MANDELL; Martin STOGNIEW; Jennifer Louise SCHMIDT; Markus SEELIG
- Web page: https://patentgrep.com/patent/US20230054211A1

## CPC

- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

## Claims

### Claim at position 1

-70. (canceled)

### Claim 71

A method of treating and/or preventing post-traumatic stress disorder (PTSD) and/or ameliorating a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of methylone (3,4-methylenedioxy-N-methylcathinone) to the subject.

### Claim 72 (depends on 71)

The method of claim 71, wherein the PTSD is treatment-resistant.

### Claim 73 (depends on 71)

The method of claim 71, wherein methylone is administered in a dose of 50-1,000 mg.

### Claim 74 (depends on 71)

The method of claim 71, wherein methylone is administered in a dose of 0.8-30 mg/kg.

### Claim 75 (depends on 71)

The method of claim 71, wherein the subject is suicidal.

### Claim 76 (depends on 71)

The method of claim 71, wherein the methylone is used in combination with an additional therapy for PTSD.

### Claim 77 (depends on 76)

The method of claim 76, wherein the additional therapy is psychotherapy.

### Claim 78 (depends on 76)

The method of claim 76, wherein the additional therapy comprises administering one or more additional psychoactive agents to the subject.

### Claim 79 (depends on 78)

The method of claim 78, wherein the additional psychoactive agents are selected from the group consisting of selective-serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin-norepinephrine-dopamine reuptake inhibitors (SDNRIs), and anxiolytic agents.

### Claim 80 (depends on 79)

The method of claim 79, wherein the additional psychoactive agent is a selective-serotonin reuptake inhibitor (S SRI).

### Claim 81 (depends on 80)

The method of claim 80, wherein the subject is taking or is continuing to take the SSRI concurrently with the methylone.

### Claim 82 (depends on 71)

The method of claim 71, wherein the methylone is administered weekly.

### Claim 83 (depends on 71)

The method of claim 71, wherein the administering step comprises administering an initial dose of methylone, which is then boosted 30 minutes-4 hours later by administering a second methylone dose in an amount that is about 10%-100% of the initial dose.

### Claim 84

A method of treating and/or preventing a Depressive Disorder and/or ameliorating a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of methylone (3,4-methylenedioxy-N-methylcathinone) to the subject.

### Claim 85 (depends on 25)

The method of claim 25, wherein the Depressive Disorder is selected from the group consisting of Disruptive Mood Dysregulation Disorder, Major Depressive Disorder, Single and Recurrent Episodes, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance/Medication-Induced Depressive Disorder, Depressive Disorder Due to Another Medical Condition, Other Specified Depressive Disorder, Unspecified Depressive Disorder, and combinations thereof.

### Claim 86 (depends on 84)

The method of claim 84, wherein the Depressive Disorder is treatment-resistant.

### Claim 87 (depends on 84)

The method of claim 84, wherein methylone is administered in a dose of 50-1,000 mg.

### Claim 88 (depends on 84)

The method of claim 84, wherein methylone is administered in a dose of 0.8-30 mg/kg.

### Claim 89 (depends on 84)

The method of claim 84, wherein the subject is suicidal.

### Claim 90 (depends on 84)

The method of claim 84, wherein the methylone is used in combination with an additional therapy for the Depressive Disorder.

### Claim 91 (depends on 90)

The method of claim 90, wherein the additional therapy is psychotherapy.

### Claim 92 (depends on 90)

The method of claim 90, wherein the additional therapy comprises administering one or more additional psychoactive agents to the subject.

### Claim 93 (depends on 92)

The method of claim 92, wherein the additional psychoactive agents are selected from the group consisting of selective-serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin-norepinephrine-dopamine reuptake inhibitors (SDNRIs), and anxiolytic agents.

### Claim 94 (depends on 92)

The method of claim 92, wherein the additional psychoactive agent is a selective-serotonin reuptake inhibitor (S SRI).

### Claim 95 (depends on 94)

The method of claim 94, wherein the subject is taking or is continuing to take the SSRI concurrently with the methylone.

### Claim 96 (depends on 84)

The method of claim 84, wherein the methylone is administered weekly.

### Claim 97 (depends on 84)

The method of claim 84, wherein the administering step comprises administering an initial dose of methylone, which is then boosted 30 minutes-4 hours later by administering a second methylone dose in an amount that is about 10%-100% of the initial dose.

### Claim 98

A method of treating and/or preventing acute stress disorder and/or ameliorating a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of methylone (3,4-methylenedioxy-N-methylcathinone) to the subject.
